Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -263K | 0 | 0 | 0 | 0 |
| Operating Income | -120M | -105M | -84M | -39M | -25M |
| EBITDA | -119M | -104M | -83M | -39M | -25M |
| Net Income | -104M | -89M | -72M | -38M | -25M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$49.19
+2.97% today
1Y Change
+125.84%
Window
Jun 26, 2025 → Jun 23, 2026
Coverage: 248 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Enliven Therapeutics, Inc. (ELVN) is a Healthcare stock with a market cap of $2.53B and listed on NASDAQ. The stock last traded around $49.19 and up 125.8% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +3.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +3.2%, free cash flow +3.8% with operating margin 0.0% and ROIC -26.0%. Stock Foundry combines ELVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELVN
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELVN Max Drawdown
-36.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ELVN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$24.7M
+34.3% YoY
Free Cash Flow
-$19.3M
+40.9% YoY
Revenue Growth
+0.0%
EPS Growth
+3.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -263K | 0 | 0 | 0 | 0 |
| Operating Income | -120M | -105M | -84M | -39M | -25M |
| EBITDA | -119M | -104M | -83M | -39M | -25M |
| Net Income | -104M | -89M | -72M | -38M | -25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99M | 124M | 100M | 76M | 110M |
| Total Assets | 476M | 326M | 272M | 83M | 113M |
| Total Liabilities | 17M | 16M | 26M | 160M | 6M |
| Shareholder Equity | 460M | 310M | 246M | -77M | 107M |
| Total Debt | 399K | 0 | 335K | 323K | 159K |
| Net Debt | -98M | -124M | -100M | -75M | -110M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
19M
+40.3% YoY
Capital Expenditures
191K
+68.8% YoY
Free Cash Flow
19M
+40.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.